

CLAIMS

5 What is claimed is:

1. A dosage form comprising an alpha-2-adrenergic agonist and a trefoil factor family peptide.
2. The dosage form of claim 1 wherein said dosage form is a solid.
3. The dosage form of claim 1 wherein said dosage form is a liquid.
- 10 4. The dosage form of claim 1 wherein said dosage form is a liquid suspension.
5. The dosage form of claim 4 wherein the concentration of the alpha-2 adrenergic agonist is from 0.1% to 2%.
- 15 6. The method of claim 4 wherein the concentration of the trefoil factor family peptide is from 0.1% to 1%.
7. The dosage form of claim 1 wherein said alpha-2-adrenergic agonist is selected from the group consisting of imidazole -2-thiones, quinoxaline derivatives, imino-imidazolines, imidazolines, imidazoles, azepines, thiazines, oxazolines, guanidines, catecholamines, and mixtures thereof, or is a 20 pharmaceutically acceptable salt thereof.
8. The dosage form of claim 1 wherein said alpha-2-adrenergic agonist comprises brimonidine or a pharmaceutically acceptable salt thereof.
9. The dosage form of claim 1 which further comprises a mucoadhesive agent.
- 25 10. The dosage form of claim 1 wherein the trefoil factor family peptide is TFF1.
11. The dosage form of claim 1 wherein the trefoil factor family peptide is TFF2.
12. The dosage form of claim 1 wherein the trefoil factor family peptide is 30 TFF3.
13. A method of treating glaucoma or reducing intraocular pressure comprising topically administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to an eye of a mammal suffering from glaucoma.

14. The method of claim 13 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in separate compositions.
15. The method of claim 13 wherein said alpha-2-adrenergic agonist and said trefoil factor family peptide are administered in a single composition.
- 5 16. A method of treating a gastrointestinal disorder comprising administering an alpha-2-adrenergic agonist and a trefoil factor family peptide to a mammal suffering from said disorder.
17. The method of claim 16 wherein the gastrointestinal disorder comprises Crohn's disease, ulcerative colitis, gastritis, irritable bowel disease and chronic
- 10 10 visceral pain.
18. The method of claim 16 wherein the gastrointestinal disorder comprises ulcerative colitis.
19. The method of claim 16 wherein the gastrointestinal disorder comprises irritable bowel disease.